USANA Health Sciences Increases Share Repurchase Authorization by $30 Million

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced that its board of directors has authorized an additional $30 million in funding for share repurchases of its outstanding common stock.

“The Board’s authorization of additional funding for our stock repurchase program is an indication of our confidence in both the short- and long-term growth potential of the Company. We will continue to explore opportunities to build long-term value for all of our stakeholders.”

Repurchases may be made from time to time, in the open market, through block trades or otherwise. The number of shares to be purchased and the timing of purchases will be based on market conditions, the level of cash balances, general business opportunities and other factors. Today's $30 million authorization will be in addition to the approximately $6 million that are remaining under the prior authorization as of the end of the second quarter of 2011.

Dave Wentz, Chief Executive Officer, said, "The Board’s authorization of additional funding for our stock repurchase program is an indication of our confidence in both the short- and long-term growth potential of the Company. We will continue to explore opportunities to build long-term value for all of our stakeholders."

About USANA

USANA develops and manufactures high-quality nutritional, personal care and weight-management products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, and the United Kingdom. Additionally, USANA’s wholly owned subsidiary, BabyCare, Ltd., operates a direct selling business in China. More information on USANA can be found at http://www.usanahealthsciences.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.